KYNB:NASDAQ
Kyntra Bio Inc
US$6,90
arrow_downward
-1,84%(-0,13) 1 HR
29 Mei, 16.00.00 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk KYNB...
Buka
US$7,05
Tinggi
US$7,05
Rendah
US$6,86
Kapitalisasi pasar
27,93 jt
Volume rata-rata
7,82 rb
Volume
6,65 rb
Rasio P/E
0,17
Harga tinggi dalam 52 minggu terakhir
US$9,70
Harga rendah dalam 52 minggu terakhir
US$6,32
EPS
US$40,46
Beta
1,04
Saham beredar
4,05 jt
Jumlah karyawan
34
Buka
US$7,05
Tinggi
US$7,05
Rendah
US$6,86
Kapitalisasi pasar
27,93 jt
Volume rata-rata
7,82 rb
Volume
6,65 rb
Rasio P/E
0,17
Harga tinggi dalam 52 minggu terakhir
US$9,70
Harga rendah dalam 52 minggu terakhir
US$6,32
EPS
US$40,46
Beta
1,04
Saham beredar
4,05 jt
Jumlah karyawan
34
Artikel berita
Dari berbagai sumber di seluruh web
Simply Wall Street
·
14 menit yang lalu
Eos Energy Ties 2 GWh Storage Deal To Long Term Growth Story
Yahoo Finance
·
58 menit yang lalu
The S&P 500 returns 10% on average, but your mortgage costs 6.36% — here's what the math says to do
Seeking Alpha
·
1 jam yang lalu
The June Dog Of The Dow To Buy
CNBC
·
1 hari yang lalu
Berkshire trails red-hot S&P 500 by biggest margin so far this year
Profil
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Tentang Kyntra Bio Inc
CEO-
Karyawan34
Didirikan1 Jan 1993
Kantor PusatSan Francisco, California, Amerika Serikat
Sektor-
Situsfibrogen.com
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut